Amgen

News

Amgen and AstraZeneca's fast-growing asthma drug Tezspire is now poised to take on rival Dupixent in chronic rhinosinusitis with nasal polyps.

News

This week saw both Gilead Sciences and Amgen start to fulfil pledges to step up capital investments in new US facilities.

News

Shares in Sanofi have fallen after it reported data from a phase 3 trial of atopic dermatitis drug amlitelimab – even though it met all objectives.

News

Four years after buying Five Prime for $1.9bn, Amgen has promising phase 3 results with a gastric cancer drug that was the focal point for the deal.

News

Italfarmaco's oral HDAC inhibitor Duvyzat has been recommended for approval in the EU as a treatment for Duchenne muscular dystrophy (DMD).

News

The first biosimilars of AstraZeneca/Alexion's blockbuster complement C5 inhibitor Soliris have been launched in the US at a discount to the brand.